CSIMarket Company Name, Ticker, Customers, else..
 
Blueprint Medicines Corporation  (BPMC)
Other Ticker:  
 
 
Price: $87.5800 $0.10 0.114%
Day's High: $88.3 Week Perf: -0.56 %
Day's Low: $ 86.57 30 Day Perf: 1.85 %
Volume (M): 400 52 Wk High: $ 121.90
Volume (M$): $ 34,997 52 Wk Avg: $88.63
Open: $87.70 52 Wk Low: $43.89



 Market Capitalization (Millions $) 5,505
 Shares Outstanding (Millions) 63
 Employees 582
 Revenues (TTM) (Millions $) 369
 Net Income (TTM) (Millions $) -205
 Cash Flow (TTM) (Millions $) -16
 Capital Exp. (TTM) (Millions $) 15

Blueprint Medicines Corporation
Blueprint Medicines Corporation is a biopharmaceutical company that specializes in developing precision therapies for patients with genetically defined diseases. The company was founded in 2011 and is headquartered in Cambridge, Massachusetts. Blueprint Medicines focuses on developing small molecule drugs that target specific genetic abnormalities or pathways associated with diseases.

The company's main area of focus is targeted oncology, with a particular emphasis on developing therapies for patients with gastrointestinal stromal tumors (GIST) and other solid tumor types. Blueprint's lead product, Ayvakit (avapritinib), is a small molecule kinase inhibitor that has been approved by the US FDA for the treatment of patients with GIST who have a specific mutation called PDGFRA exon 18.

Blueprint Medicines has several other programs in development, including BLU-285, a potent inhibitor of KIT and PDGFRA kinase mutations that are resistant to current therapies. The company is also developing an investigational drug, BLU-667, which targets RET, a genetic driver of non-small cell lung cancer and thyroid cancer.

In addition to oncology, Blueprint Medicines is also developing therapies for patients with rare genetic diseases including fibrodysplasia ossificans progressiva (FOP) and achondroplasia, which are both caused by specific genetic mutations.

Notably, Blueprint Medicines has established partnerships with other biopharmaceutical companies, including Roche and CStone Pharmaceuticals, for the development and commercialization of its investigational drug candidates.

Overall, Blueprint Medicines Corporation is a leading biopharmaceutical company that is dedicated to developing precision medicines for patients with genetically defined diseases. Through its innovative approach to drug discovery and development, Blueprint Medicines has the potential to transform the lives of patients living with cancer and rare genetic diseases.


   Company Address: 45 Sidney Street Cambridge 2139 MA
   Company Phone Number: 374-7580   Stock Exchange / Ticker: NASDAQ BPMC


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
• View Complete Report
   



Blueprint Medicines Corporation

Blueprint Medicines Corporation Achieves Remarkable Financial Growth in Fiscal Year Ending March 31, 2024

The fiscal results for the period ending March 31, 2024, for this Major Pharmaceutical Preparations company paints a positive picture of the company's financial health and performance. The most striking improvement is the company's turnaround to profitability, with earnings per share (EPS) of $1.40 compared to a loss of $-2.15 per share in the previous year. This positive trend is further highlighted by a shift in earnings per share from -$1.79 in the prior reporting period.
Revenue also saw a significant increase, rising by 67.251% to $96.12 million from $57.47 million in the same period the year before. Sequentially, revenue improved by 23.581% from $77.78 million. This demonstrates strong growth in the company's top line and reflects positively on its business operations and market performance.
Blueprint Medicines Corporation

Blueprint Medicines Corporation Achieves Extraordinary Financial Growth, Smashing Expectations in Q4

Blueprint Medicines Corporation, a major player in the pharmaceutical preparations industry, has shown impressive performance in its financial fourth quarter of 2023. The company managed to decrease its loss per share, with a reduction from $-2.60 a year ago to $-1.79 per share. This improvement in EPS demonstrates the company's commitment to achieving profitability.
Additionally, revenue for the financial fourth quarter surged by a remarkable 163.282% to $77.78 million, compared to $29.54 million in the corresponding reporting season a year ago. Sequentially, revenue also experienced a substantial increase of 37.496% from $56.57 million. These impressive revenue numbers outperformed the Major Pharmaceutical Preparations industry contemporaries, which reported only 3.00% business growth during the same period. It is evident that Blueprint Medicines Corporation is excelling in its industry and capturing a larger market share.
Blueprint Medicines Corporation

Disappointing Earnings at BPMC Shake Up the Stock Market in Q3 2023



The stock market is filled with unpredictable twists and turns, and discerning investors are always on the lookout for key financial indicators that can help them make informed decisions. In this article, we will delve into the latest quarterly report of Blueprint Medicines Corporation (BPMC), a leading pharmaceutical company, and highlight some interesting facts that may impact the stock market.
1. Increased Losses:
When assessing a company's financial health, the bottom line is a crucial measure. In the fiscal third quarter of 2023, BPMC reported a loss of $-2.20 per share. While this is an improvement compared to the previous year's loss of $-2.23 per share, it is still higher than the loss of $-2.19 per share observed in the preceding quarter. This suggests that BPMC is not yet on a path towards profitability.
Blueprint Medicines Corporation

Blueprint Medicines Corporation Reports Narrowed Deficit and Strong Revenue Growth in Q2 2023 Despite Challenging Market Dynamics

Financial Interval Closing June 30, 2023: Blueprint Medicines Corporation Reports Increased Revenue and Decreased Net Deficit
In the financial interval closing June 30, 2023, Blueprint Medicines Corporation experienced a decrease in net loss per share compared to the same quarter a year ago. The company reported a loss of -$2.19 per share, which is an improvement from the loss of -$2.68 per share in the previous year. Additionally, the net deficit decreased from -$2.15 per share in the prior quarter.
Despite the loss per share improvement, Blueprint Medicines Corporation achieved a strong increase in revenue. The company's revenue rose by 55.704% to $57.57 million in the current quarter, compared to $36.97 million in the same quarter a year ago. Additionally, there was a sequential revenue growth of 0.177% from $57.47 million.
Blueprint Medicines Corporation

Major Pharmaceutical Preparations Company Suffers Heavy Losses in Fiscal Q1 2023

Blueprint Medicines Corporation is a medical research company that specializes in developing and commercializing precision therapies for genetically defined diseases. The company's focus is on developing treatments for conditions such as cancer, rare genetic disorders, and autoimmune diseases, which often have limited treatment options.
Despite the company's impressive clinical pipeline, the past year has been challenging for Blueprint Medicines Corporation. The company reported a cumulative net loss of $-581 million during the 12 months ending in the first quarter of 2023, resulting in a negative return on assets (ROA) of -41.88%. This puts the company behind the Healthcare sector as a whole, with 203 other companies having a higher return on assets.






Blueprint Medicines's Segments





Help

About us

Advertise
CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com